Back to Authors

Wang, M. L.

A5086537029 | I1343551460

Mayo Clinic

The University of Texas MD Anderson Cancer Center

Citations 3

PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS, SUBGROUP ANALYSIS FROM BRUIN WITH >3 YEARS FOLLOW‐UP FROM START OF ENROLLMENT

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 153-156

10.1002/hon.3163_102

P1100: BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MCL (TRIAL IN PROGRESS)

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 990-991

10.1097/01.hs9.0000847268.67095.fc

P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 991-992

10.1097/01.hs9.0000847272.47630.ff